Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients

Brii Biosciences Adds Us$100 Million To Advance Its Late Stage Monoclonal Antibody Combination Therapy, Brii 196/brii 198, For Non Hospitalized Covid 19 Patients

Facebook Comments

Leave a Reply

CommentLuv badge